Home＞REGULATORY
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab(Apr.17.2018)
Pharma industry leaders at public-private dialogue |
Chieftains of major drug makers and industry associations fired off a barrage of complaints against the 2018 drug pricing reform package at their new policy dialogue forum with senior health ministry officials on April 16, with Eisai CEO Hauro Naito warning that Japan is “sinking” as a drug discovery powerhouse ...
(LOG IN FOR FULL STORY)
-
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification Apr.17
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
